Aditxt ROIC

Mitä Aditxt tekee? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt on yksi Eurpooliin suosituimmista yhtiöistä.